Recently the department acquired two californium-252 sources for use in partial body in vivo activation analysis. Each source of 200 ,ug 252Cf, emitting approximately 4 x 108 neutrons/sec, is encapsulated in a small cylindrical steel container, 1.0 cm x 0.7 cm diameter. A pneumatic system is used to transfer each source independently from the storage location to the desired irradiation position.
The conditions for activation have been investigated by examining the influence of premoderators, reflectors and air gaps on the uniformity of activation and on the sensitivity for the measurement of iodine. These investigations together with dose measurements show (Boddy et al. 1974 ) that irradiation and monitoring periods each of 20 minutes are necessary to obtain a sufficient level of sensitivity per unit dose. Depending on the actual compromise chosen between sensitivity and activation uniformity, the error for the measurement of 10 mg of iodine ranged from 8.3% to 3.4% while the total radiation dose ranged from 10 to 23 rem. The corresponding values for the minimum detectable amount were 1.7 and 0.6 mg I.
While it appears that the reactor spectrum is more suitable for the activation of iodine in the thyroid, nevertheless californium-252 could be used satisfactorily in a technique for the measurement of intrathyroidal iodine. This report has dealt only with the measurement of iodine in the thyroid gland; however, it has been shown (Boddy et al. 1974 ) that californium-252 can be used effectively in the measurement of other body elements, principally the measurement of calcium in sections of the limbs. Obviously californium-252 has considerable potential importance in partial body in vivo activation analysis: much of this importance must be related to the ease with which californium sources could be installed and used in the clinical environment. The recent introduction of the 99Tcm-labelled phosphate compounds has made high quality bone scans available in all hospitals with scanning facilities . Bone scanning may be particularly useful in the study of breast cancer because of the high incidence of bone metastases in this condition (Jaffe 1958) , and the ability of the scan to identify metastases while radiographs are still normal (Charkes et al. 1968 ). Using 15 mCi of 99Tcm-EHDP, which appears to be the most favourable of the 99Tcmphosphates (Citrin et al. 1975 ), a gamma camera axial skeleton scan (Galasko et al. 1968 ) is completed within 30-45 minutes. After the initial intravenous administration of radiopharmaceutical the procedure is entirely non-invasive. Outpatient studies are easily performed.
We have scanned 178 patients with breast cancer and our results confirm a higher incidence of metastases observed with the scan than with conventional radiography: all but two of 47 patients with known X-ray positive lesions were also scan positive and in 24 (50 %) the scan showed more widespread disease than the radiograph. In 60 patients where metastases were clinically suspected but radiographs showed no definite abnormality, the scan was positive in 29 (49%). Follow up of these patients has been undertaken and we have confirmed the presence of metastases at the sites initially indicated by the scan in several patients.
To date 71 patients with primary breast cancer have been studied with 99Tcm-EHDP. Bone scans were performed as part of the initial assessment before surgical treatment of the primary disease; 23 (33%) have definite scan evidence of skeletal metastases. In no patient did a conventional radiographic skeletal survey, reported by an experienced consultant radiologist, show evidence of metastatic disease. Clinical staging of the 23 patients is shown in Table 1 . It is clear that bone scanning can provide evidence of dissemination in many patients with apparently early breast cancer.
A prospective study of patients with primary breast cancer is in progress at Glasgow Royal Infirmary. The study is designed to determine the precise prognostic significance of a positive (and negative) bone scan in the assessment of primary breast cancer patients. Our preliminary results suggest that the lesions demonstrated do represent clinically significant metastatic disease. Because of the convenience and safety of 9aTcm-EHDP, serial scans are possible. We scan all our post-mastectomy patients at regular sixmonthly intervals, or more frequently if there is any clinical suspicion of local recurrence or metastases. There appears to be emerging a group of patients in whom serial scans reveal progression of occult metastases during what would previously be considered a 'tumour-free' interval, when clinical symptoms and signs are absent and skeletal radiographs are normal. The therapeutic significance of such early diagnosis must now be considered.
In the treatment of established bone metastases it has been suggested that the scan may provide evidence of response to systemic therapy (Galasko & Doyle 1972) . For these purposes we have developed a simple non-invasive method for quantitating the activity of skeletal lesions, independent of the variable exposure of the gamma camera polaroid scan (Citrin, Bessent, Tuohy, Greig & Blumgart 1974) .
We are now using this method to study the response of occult metastases to systemic treatment. We believe the method may be particularly valuable in the management of asymptomatic radiologically normal scan positive patients in whom there may be no other available method for assessing therapeutic effects.
The ability to demonstrate and quantitate the activity of skeletal metastases in a patient with an 'early' breast tumour or a patient who remains well after an apparently -successful primary operation, introduces entirely new therapeutic opportunities. It is possible that serial quantitative bone scans may provide a rapid means of determining whether a particular therapy will be of value in inducing a remission. Further research is now urgently needed to establish whether the improved diagnostic accuracy of the bone scan will reduce the morbidity and mortality of breast cancer, by facilitating earlier and more appropriate treatment.
Dr M V Merrick (RoyalPostgraduate Medical School, London W12; Western General Hospital, Edinburgh, EH4 2XU) An Appraisal ofImaging Methods to Detect Disease ofthe Adrenal Glands, the Pancreas and the Parathyroids Of the three investigations listed in the title, only pancreas scanning is widely used at the present time. There is no known substance which accumulates exclusively in the pancreas, although there are a number which concentrate to a greater extent in this organ than they do in the liver. Various such compounds have been investigated, but only one has established itself clinically, namely selenomethionine. This is the aminoacid methionine, with the sulphur atom replaced by a selenipm atom. It is synthesized by microorganisms growing in an environment depleted in sulphur and enriched in selenium. The final product is not pure selenomethionine but is a mixture of natural aminoacids, selenomethionine and sodium-selenite.
There is considerable disagreement between various centres on the accuracy of pancreas scanning. Figures as low as 37 % (Rankin & Brown 1964) and as high as 90% (Asnies & Johansen 1970) have been quoted in different series. There can be little doubt that this does to some extent reflect-differences in selection of patients for this investigation, but may also be due to differences in the technique employed. There are four possible ways of scanning the pancreas: (1) A straightforward rectilinear scan using only selenomethionine. (2) A rectilinear scan after the administration of both seleno-
